Drugs / Insulin glargine/Lixisenatide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03798080 | Feb 2019 → Dec 2020 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Insulin glargine/Lixisenatide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03798080 ↗ |
| Known as | HOE901/AVE0010 | “Insulin glargine/Lixisenatide (HOE901/AVE0010)” NCT03798080 ↗ |
| Route | Subcutaneous | “Route of administration: subcutaneous” NCT03798080 ↗ |